I-Mab
NASDAQ:IMAB
I-Mab
NASDAQ:IMAB
Price:
1.8 USD
Market Closed
Updated:
Apr 24, 2024
Section:
Intrinsic Value
I-Mab operates as a clinical stage biopharmaceutical company. [ Read More ]
The intrinsic value of one
IMAB
stock under the Base Case scenario is
39.77
USD.
Compared to the current market price of 1.8 USD,
I-Mab
is
Undervalued by 95%.
Key Points:
IMAB
Intrinsic Value
Base Case
39.77
USD
Undervaluation 95%
Key Points
Market Cap
I-Mab's market capitalization is 145.3m USD.
Price
IMAB stock price is 1.8 USD.
Intrinsic Value
IMAB stock price (1.8 USD) is 95% less than its Intrinsic Value (39.77 USD).
DCF Value
We can't calculate DCF Value for IMAB. Open DCF Valuation
IMAB. Open DCF Valuation
Relative Value
Wall St Target
There are no price targets for IMAB.
IMAB.
Negative 1-Year Revenue Growth
IMAB's Revenue has dropped by 112% over the past 12 months.
Declining ROE
IMAB's ROE (Return on Equity) has significantly decreased in the last 3 years from 20% to -63%.
ROIC is Increasing
IMAB's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from 16% to 2 211%.
Negative Operating Income
IMAB has negative Operating Income for the last twelve months.
Negative Net Income
IMAB has negative Net Income for the last twelve months.
Negative ROE
IMAB's ROE (Return on Equity) for the past 12 months is negative and is equal to -63%.
Exceptional ROIC
IMAB's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 2 211%.
Positive Gross Profit
IMAB has positive Gross Profit for the last twelve months.
Exceptional Revenue Growth Forecast
IMAB's Revenue is forecast to grow at a rate of 281% per year over the next 3 years.
Long-Term Solvency
IMAB's long-term assets (3B CNY) exceed its long-term liabilties (895m CNY).
Negative Free Cash Flow
IMAB has negative Free Cash Flow for the last twelve months.
Negative 3-Years Revenue Growth
IMAB's Revenue has been falling by 74% per year for the last 3 years.
Exceptional 3-Year Average ROIC
IMAB has very high three-year average ROIC (Return on Invested Capital): 49%. The company is very efficient at using invested capital to generate operating income.
Low D/E
IMAB's D/E (Debt to Equity) is very low and is equal to 0.02.
Negative 3-Year Average ROE
IMAB has negative three-year average ROE (Return on Equity): -41%. The company is not efficient at transforming stockholders' equity into net income.
Short-Term Solvency
IMAB's short-term assets (2B CNY) exceed its short-term liabilties (412m CNY).
Negative Net Debt
IMAB has negative Net Debt. This means that the company has more cash and short-term investments (2B CNY) than debt (30m CNY).
Low Altman Z-Score
IMAB's Altman Z-Score is very low and is equal to -6.06.
Low Interest Coverage
IMAB doesn't generate enough operating income (-1B CNY) to safely cover interest payments on its debt (1m CNY).
Fundamental Analysis
Beta
Ask me anything about
I-Mab
Financials
Balance Sheet Decomposition
I-Mab
I-Mab
| Current Assets | 2.3B |
| Cash & Short-Term Investments | 2.3B |
| Other Current Assets | 52m |
| Non-Current Assets | 276.3m |
| Long-Term Investments | 12.1m |
| PP&E | 82.9m |
| Intangibles | 118.1m |
| Other Non-Current Assets | 63.2m |
| Current Liabilities | 411.8m |
| Accounts Payable | 357.8m |
| Accrued Liabilities | 21.9m |
| Short-Term Debt | 30m |
| Other Current Liabilities | 2.2m |
| Non-Current Liabilities | 483m |
| Other Non-Current Liabilities | 483m |
Efficiency
Earnings Waterfall
I-Mab
I-Mab
|
Revenue
|
27.6m
CNY
|
|
Cost of Revenue
|
0
CNY
|
|
Gross Profit
|
27.6m
CNY
|
|
Operating Expenses
|
-1.3B
CNY
|
|
Operating Income
|
-1.2B
CNY
|
|
Other Expenses
|
-229.7m
CNY
|
|
Net Income
|
-1.5B
CNY
|
Free Cash Flow Analysis
I-Mab
What is Free Cash Flow?
I-Mab
Fundamental Scores
IMAB Profitability Score
Profitability Due Diligence
Profitability Due Diligence
I-Mab's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Exceptional 3-Year Average ROIC
Exceptional Revenue Growth Forecast
Positive Gross Profit
Exceptional ROIC
40/100
Profitability
Score
Score
I-Mab's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
IMAB Solvency Score
Solvency Due Diligence
Solvency Due Diligence
I-Mab's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
53/100
Solvency
Score
Score
I-Mab's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMAB Price Targets Summary
I-Mab
I-Mab
There are no price targets for IMAB.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
IMAB Analyst Estimates
View Analyst Estimates
Shareholder Return
IMAB Price
I-Mab
I-Mab
Annual Price Range
1.8
52w Low
1.18
52w High
3.34
Price Metrics
| Average Annual Return | 58.23% |
| Standard Deviation of Annual Returns | 182.65% |
| Max Drawdown | -99% |
Shares Statistics
| Market Capitalization | 145.3m USD |
| Shares Outstanding | 80 701 600 |
| Percentage of Shares Shorted | 1.86% |
Company Profile
I-Mab
Country
China
Industry
Biotechnology
Market Cap
145.3m USD
Dividend Yield
0%
Description
I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.
Contact
SHANGHAI
Shanghai
55Th-56Th Floor, New Bund Center, 555 West Haiyang Road, Pudong District
+862160578000.0
http://www.i-mabbiopharma.com/en
IPO
2020-01-17
Employees
228
Officers
CEO & Director
Mr. Raj Kannan
Co-Founder & Chief Scientific Officer
Dr. Jerry Wang
Chief Financial Officer
Mr. Skelton Joseph
Vice President of Investor Relations
Mr. Tianyi Zhang
Chief Legal Officer
Mr. Cheng Li
Chief Communications Officer
Ms. Gigi Qi Feng
Show More
Executive VP of Global Business Development & Chief Business Officer
Dr. Weiming Tang Ph.D.
Senior VP and Head of U.S. & EU Business Development
Dr. Fernando J. Salle´s Ph.D.
Head of US site
Claire Xu
Chief Medical Officer
Dr. John Hayslip M.D.
Show Less
You don't have any saved screeners yet
